Published: 21 March 2016
Author(s): Guillaume Moulis, Johanne Germain, Daniel Adoue, Odile Beyne-Rauzy, Hélène Derumeaux, Laurent Sailler, Maryse Lapeyre-Mestre
Section: Letters to the Editor
Immune thrombocytopenia (ITP) is a rare autoimmune disorder leading to platelet destruction and inadequate platelet production, resulting in a risk of spontaneous bleeding. The incidence of ITP necessitating health care is estimated to be 2.9/100 000 inhabitants [1].